Cost-effectiveness analysis of neoadjuvant v surgery-first for resectable pancreatic cancer

Medicine and Dentistry

• Cost-Effectiveness Analysis 100%
• Pancreas Cancer 100%
• Patient 100%
• Surgery 100%
• Health Care Cost 31%
• Therapeutic Procedure 26%
• Neoadjuvant Therapy 21%
• Adjuvant Therapy 15%
• Life 15%
• Disease 15%
• Analysis 10%
• Quality of Life 10%
• Family 10%
• Meta-Analysis 10%
• Predictive Medicine 10%
• Clinical Decision Making 5%
• Postoperative Complication 5%
• Neoplasm 5%
• Randomized Controlled Trial 5%
• Arm 5%
• Quality Adjusted Life Year 5%
• Assessment 5%
• Death 5%
• Cancer Therapy 5%
• Malignant Neoplasm 5%
• Measurement 5%
• Sensitivity Analysis 5%
• Survival Time 5%
• Obstetric Delivery 5%
• Follow up 5%
• Random Effects Model 5%

Nursing and Health Professions

• Surgery 100%
• Cost Effectiveness Analysis 100%
• Diseases 15%
• Adjuvant Therapy 15%
• Shared Decision-Making 15%
• Systematic Review 10%
• Quality of Life 10%
• Time 10%
• Analysis 10%
• Measurement 5%
• Patient with Cancer 5%
• Neoplasm 5%
• Malignant Neoplasm 5%
• Survival Time 5%
• Follow up 5%
• Cancer Therapy 5%
• Obstetric Delivery 5%
• Clinical Decision Making 5%
• Death 5%
• Sensitivity Analysis 5%
• Deterioration 5%
• Postoperative Complication 5%